These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28138812)

  • 1. Trends in oral anticoagulant use in Qatar: a 5-year experience.
    Elewa H; Alhaddad A; Al-Rawi S; Nounou A; Mahmoud H; Singh R
    J Thromb Thrombolysis; 2017 Apr; 43(3):411-416. PubMed ID: 28138812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.
    Weitz JI; Semchuk W; Turpie AG; Fisher WD; Kong C; Ciaccia A; Cairns JA
    Clin Ther; 2015 Nov; 37(11):2506-2514.e4. PubMed ID: 26481493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
    Costa LSD; Alsultan MM; Hincapie AL; Guo JJ
    J Thromb Thrombolysis; 2023 Feb; 55(2):339-345. PubMed ID: 36401731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study.
    Zhang C; Wang J; Yang Y; Ma EL; Lin HW; Liu BL; Gu ZC
    Clin Appl Thromb Hemost; 2022; 28():10760296221132551. PubMed ID: 36250531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
    Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
    J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
    Forslund T; Wettermark B; Hjemdahl P
    Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Trends in Ambulatory Oral Anticoagulant Use.
    Barnes GD; Lucas E; Alexander GC; Goldberger ZD
    Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 11. Dawn of the direct-acting oral anticoagulants: trends in oral anticoagulant prescribing in Wales 2009-2015.
    Protty MB; Hayes J
    J Clin Pharm Ther; 2017 Apr; 42(2):132-134. PubMed ID: 28000318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.
    Lutsey PL; Walker RF; MacLehose RF; Alonso A; Adam TJ; Zakai NA
    Res Pract Thromb Haemost; 2019 Oct; 3(4):668-673. PubMed ID: 31624786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
    Baik SH; Hernandez I; Zhang Y
    J Manag Care Spec Pharm; 2016 Mar; 22(3):281-92. PubMed ID: 27003558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.
    Favaloro EJ; Pasalic L; Lippi G
    Pathology; 2017 Oct; 49(6):639-643. PubMed ID: 28826832
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.